|
|
News Breaks | | | | September 28, 2012 | | 05:55 EDT |  | SNTA, SNTA, SNTA, SNTA, SNTA, SGEN, SGEN, SGEN, SGEN, SGEN, AMGN, AMGN, AMGN, AMGN, AMGN, BMY, BMY, BMY, BMY, BMY, CELG, CELG, CELG, CELG, CELG, DCTH, DCTH, DCTH, DCTH, DCTH, DNDN, DNDN, DNDN, DNDN, DNDN, EXEL, EXEL, EXEL, EXEL, EXEL, GSK, GSK, GSK, GSK, GSK, HSP, HSP, HSP, HSP, HSP, PPHM, PPHM, PPHM, PPHM, PPHM, PFE, PFE, PFE, PFE, PFE, QGEN, QGEN, QGEN, QGEN, QGEN, VAR, VAR, VAR, VAR, VAR, RHHBY, RHHBY, RHHBY, RHHBY, RHHBY | European Society for Medical Oncology to host a conference
ESMO 2012 Congress is being held in Vienna, Austria on September 28-October 2. | |
|
News For SNTA;VAR;QGEN;PFE;PPHM;HSP;GSK;EXEL;DNDN;DCTH;CELG;BMY;AMGN;SGEN;RHHBY From The Last 14 Days Check below for free stories on SNTA;VAR;QGEN;PFE;PPHM;HSP;GSK;EXEL;DNDN;DCTH;CELG;BMY;AMGN;SGEN;RHHBY the last two weeks. |
|
|
| June 19, 2013 | | 16:01 EDT |  | PFE | Options Update; June 19, 2013
 Subscribe for More Information | | | 12:40 EDT | | SNTA | Synta Pharmaceuticals management to meet with Jefferies
Subscribe for More Information | | | 10:46 EDT |  | RHHBY | Alexion mentioned as possible target for Roche in London Times
Reference Link | | | 10:30 EDT | | PFE | Pfizer management to meet with ISI Group
Subscribe for More Information | | | 09:05 EDT |  | SGEN | Seattle Genetics, Takeda announce data from analysis of PFS with ADCETRIS
Takeda Pharmaceutical and Seattle Genetics announced data from a post-hoc analysis examining progression-free survival, PFS, following treatment with ADCETRIS versus last prior therapy in patients diagnosed with relapsed or refractory Hodgkin lymphoma post-autologous stem cell transplant or relapsed or refractory systemic anaplastic large cell lymphoma. The data were highlighted during a presentation at the 12th International Conference on Malignant Lymphoma being held June 19–22, 2013 in Lugano, Switzerland. The post-hoc analysis compared investigator assessed PFS following ADCETRIS single-agent treatment to the last prior systemic therapy in patients taking part in two pivotal Phase 2 studies. “These encouraging data suggest that ADCETRIS may delay disease progression compared to prior therapies used in this heavily pretreated patient population,” said John Radford, M.D., Professor of Medical Oncology, University of Manchester, Manchester, UK. “ADCETRIS is a CD30-targeted treatment option for patients with relapsed or refractory HL or relapsed or refractory sALCL that has shown a high overall response rate, including durable complete responses in both of its approved indications.” | | | 08:45 EDT | | RHHBY | Leerink's biotech analyst holds analyst/industry conference call on ADA
Analyst Antlaffy, along with Dr. George Grunberger, founder & Chairman of the Grunberger Diabetes Institute, preview the upcoming American Diabetes Association's conference, including perspectives on new devices in diabetes, potential disruptive technologies at ADA and progress towards the artificial pancreas on an Analyst/Industry conference call to be held on June 20 at 2 pm. | | | 07:41 EDT |  | PFE | Pfizer holders should consider Zoetis exchange, says BMO Capital
BMO Capital thinks Pfizer (PFE) investors should consider participating in the Zoetis (ZTS) exchange as they have the opportunity to own Zoetis at around $29.40-$29.70 per share, which is 15% below BMO's valuation of $34 per share. Further, BMO thinks there is strong support for Zoetis below $30, which the firm feels lowers downside risk. BMO recommends that Pfizer investors tender around 20% of their shares into the exchange, noting that with the offer likely being oversubscribed, not all tendered shares will be converted to Zoetis. | | | 05:43 EDT | | BMY | AstraZeneca, Bristol-Myers announce top line results of Phase 4 trial of Onglyza
Subscribe for More Information | | | June 18, 2013 | | 19:07 EDT | | AMGN | On The Fly: After Hours Movers
Subscribe for More Information | | | 17:25 EDT | | AMGN | Amgen reports 7.58% stake in Cytokinetics
Subscribe for More Information | | | | 09:38 EDT | | PFE | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM | | | 08:37 EDT | | GSK | Drug companies turn to microchips to test medicines, WSJ reports
Subscribe for More Information | | | 07:13 EDT | | GSK | Aspen in talks buy GSK's Arixtra, Fraxiparine brands
Subscribe for More Information | | | 07:07 EDT | | GSK | GlaxoSmithKline receives offer for thrombosis brands from Aspen
GlaxoSmithKline said it received an offer for its thrombosis brands and Notre-Dame de Bondeville site from Aspen Global. A period of exclusivity has been agreed with Aspen. The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra and Fraxiparine brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees, GSK said. "The proposed transaction is aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline," the company added. | | | June 17, 2013 | | 16:00 EDT | | PFE | Options Update; June 17, 2013
Subscribe for More Information | | | 08:36 EDT | | PFE | InSite Vision to join Merck, Pfizer patent suit against Mylan
InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. | | | 07:28 EDT | | BMY, PFE | Cambridge Healthtech Institute to host a conference
Subscribe for More Information | | | 05:44 EDT | | CELG | Celgene awarded marketing authorisation for Revlimid from EC
Subscribe for More Information | | | June 16, 2013 | | 11:44 EDT | | AMGN | Amgen still looks attractive, Barron's says
Subscribe for More Information | | | June 14, 2013 | | 16:00 EDT | | PFE | Options Update; June 14, 2013
Subscribe for More Information | | |
|
|
|
|
|
|
